HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation

Journal of Cellular Physiology

Volumn 226, Issue 12, 2011, Pages 3385-3391

  Zhang, Hong Sheng ^a   Ruan, Zheng ^a   Sang, Wei Wei ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CURCUMIN; GALACTOSIDASE; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P300; SYNAPTOTAGMIN I; TRANSACTIVATOR PROTEIN;

ACETYLATION; ARTICLE; CHROMATIN STRUCTURE; DOWN REGULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

ACETYL-COA CARBOXYLASE; ACETYLATION; AMP-ACTIVATED PROTEIN KINASES; ANTI-HIV AGENTS; BINDING SITES; CHROMATIN ASSEMBLY AND DISASSEMBLY; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENERGY METABOLISM; ENZYME ACTIVATION; HELA CELLS; HISTONE DEACETYLASE 1; HISTONES; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; I-KAPPA B KINASE; P300-CBP TRANSCRIPTION FACTORS; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80053141186     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22691     Document Type: Article

References (49)

1. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. 2006. Curcumin (diferuloylmethane) downregulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69: 195-206.
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Mol Pharmcol 4: 807-818.
3. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. 2004. Curcumin, a novel p300/CBP specific inhibitor of acetyltransferase, represses the acetylation of histones/nonhistone proteins and HAT dependent chromatin transcription. J Biol Chem 279: 51163-51171.
4. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. 1998. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 17: 7056-7065.
5. Burke TR Jr, Fesen MR, Mazumder A, Wang J, Carothers AM, Grunberger D, Driscoll J, Kohn K, Pommier Y. 1995. Hydroxylated aromatic inhibitors of HIV-1 integrase. J Med Chem 38: 4171-4178.
6. Chan MM, Huang HI, Fenton MR, Fong D. 1998. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55: 1955-1962.
7. Cho JW, Lee KS, Kim CW. 2007. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19: 469-474.
8. Cho S, Schroeder S, Kaehlcke K, Kwon HS, Pedal A, Herker E, Schnoelzer M, Ott M. 2009. Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J 28: 1407-1417.
9. Col E, Caron C, Seigneurin-Berny D, Gracia J, Favier A, Khochbin S. 2001. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem 276: 28179-28184.
10. Cota-Gomez A, Flores NC, Cruz C, Casullo A, Aw TY, Ichikawa H, Schaack J, Scheinman R, Flores SC. 2002. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem 277: 14390-14399.
11. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM. 2000. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74: 6790-6799.
12. Dandekar DH, Ganesh KN, Mitra D. 2004. HIV-1 Tat directly binds to NFkappaB enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res 32: 1270-1278.
13. Demarchi F, D'Agaro P, Falaschi A, Giacca M. 1993. In vivo footprinting analysis of constitutive and inducible protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1. J Virol 67: 7450-7460.
14. Deng L, de la Fuente C, Fu P, Wang L, Donnelly R, Wade JD, Lambert P, Li H, Lee CG, Kashanchi F. 2000. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277: 278-295.
15. D'Orso I, Frankel AD. 2009. Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. Proc Natl Acad Sci U S A 106: 3101-3106.
16. Furia B, Deng L, Wu K, Baylor S, Kehn K, Li H, Donnelly R, Coleman T, Kashanchi F. 2002. Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J Biol Chem 277: 4973-4980.
17. Goel A, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75: 787-809.
18. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652.
19. Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K. 2008. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NFkappaB activation in vascular endothelial cells. FEBS Lett 582: 1719-1724.
20. He G, Margolis DM. 2002. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 22: 2965-2973.
21. Hottiger MO, Nabel GJ. 1998. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol 72: 8252-8256.
22. Kaehlcke K, Dorr A, Hetzer-Egger C, Kiermer V, Henklein P, Schnoelzer M, Loret E, Cole PA, Verdin E, Ott M. 2003. Acetylation of Tat defines a cyclinT1- independent step in HIV transactivation. Mol Cell 12: 167-176.
23. Kimpton J, Emerman M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66: 2232-2239.
24. Leghmari K, Bennasser Y, Bahraoui E. 2008. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur J Cell Biol 87: 947-962.
25. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. 1993. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A 90: 1839-1842.
26. Li M, Zhang Z, Hill DL, Wang H, Zhang R. 2007. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67: 1988-1996 .
27. Lusic M, Marcello A, Cereseto A, Giacca M. 2003. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 22: 6550-6561.
28. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. 1995. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 49: 1165-1170.
29. Meghana K, Sanjeev G, Ramesh B. 2007. Curcumin prevents streptozotocin-induced islet damage by scavenging free radicals: a prophylactic and protective role. Eur J Pharmacol 577: 183-191.
30. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou MM. 2002. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 9: 575-586.
31. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E. 1999. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 9: 1489-1492.
32. Ott M, Dorr A, Hetzer-Egger C, Kaehlcke K, Schnolzer M, Henklein P, Cole P, Zhou MM, Verdin E. 2004. Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation. Novartis Found Symp 259: 182-193.
33. Roof P, Ricci M, Genin P, Montano MA, Essex M, Wainberg MA, Gatignol A, Hiscott J. 2002. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology 296: 77-83.
34. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K. 2008. SIRT1 longevity factor suppresses NF-kappaB -driven immune responses: regulation of aging via NF-kappaB acetylation? BioEssays 30: 939-942.
35. Shao ZM, Shen ZZ, Liu CH, Sartippour MR, Go VL, Heber D, Nguyen M. 2002. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 98: 234-240.
36. Sheridan PL, Mayall TP, Verdin E, Jones KA. 1997. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 11: 3327-3340.
37. Shishodia S, Singh T, Chaturvedi MM. 2007. Modulation of transcription factors by curcumin. Adv Exp Med Biol 595: 127-148.
38. Sui Z, Salto R, Li J, Craik C. Ortiz de Montellano PR. 1993. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem 1: 415-422.
39. Sun Y, Huang YC, Xu QZ, Wang HP, Bai B, Sui JL, Zhou PK. 2006. HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation. Int J Radiat Oncol Biol Phys 65: 842-850.
40. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15: 1112-1120.
41. Verdin E, Paras P Jr, Van Lint C. 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12: 3249-3259.
42. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92: 451-462.
43. Weissman JD, Brown JA, Howcroft TK, Hwang J, Chawla A, Roche PA, Schiltz L, Nakatani Y, Singer DS. 1998. HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci USA 95: 11601-11606.
44. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18: 1101-1108.
45. Zhang HS, Wang SQ. 2007. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem Pharmacol 73: 1358-1366.
46. Zhang HS, Wu MR. 2009. SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase. Virus Res 146: 51-57.
47. Zhang HS, Li HY, Zhou Y, Wu MR, Zhou HS. 2009a. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation. Free Radic Biol Med 47: 261-268.
48. Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F. 2009b. Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity. Life Sci 85: 484-489.
49. Zhang HS, Sang WW, Wang YO, Liu W. 2010. Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation. J Cell Biochem 110: 1464-1470.